Scarica l'app Stockscreener
27.57
2.80%
0.75
Uniqure Nv Borsa (QURE) Ultime notizie
RSU grant, options and tax sale for uniQure (NASDAQ: QURE) director - Stock Titan
uniQure (QURE) director trades shares, receives RSUs and stock options - Stock Titan
Tax-related share sale by uniQure (NASDAQ: QURE) chief customer officer - Stock Titan
uniQure (QURE) director receives RSUs, stock options and sells shares for taxes - Stock Titan
uniQure (QURE) director Leonard Post awarded RSUs, options and sells shares for taxes - Stock Titan
Director Jack Kaye at uniQure (QURE) gets RSUs and options, sells shares for taxes - Stock Titan
Equity awards and tax-driven share sale for uniQure (NASDAQ: QURE) director - Stock Titan
uniQure (NASDAQ: QURE) director awarded RSUs, sells shares for taxes - Stock Titan
What Caused uniQure's Dramatic Stock Plunge - Kavout
[144] uniQure N.V. SEC Filing - Stock Titan
UniQure (NASDAQ: QURE) reports 7,970 RSUs vest and 10,000-share 10b5-1 sale - Stock Titan
UniQure N.V. (QURE) files Rule 144 to sell 7,970 RSU shares on 06/11/2026 - Stock Titan
Jack Kaye sale notice at UniQure (NASDAQ: QURE) — 7,970 shares proposed - Stock Titan
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
Trading the Move, Not the Narrative: (QURE) Edition - Stock Traders Daily
Fiera Capital Corp Invests $18.39 Million in uniQure N.V. $QURE - MarketBeat
Why Did QURE Stock Almost Halve Pre-Market Today? - Stocktwits
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
What Just Happened with uniQure's Earnings and FDA Update - Kavout
QURE Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesWeak Earnings Momentum - newsline.com
Director Kaye trades uniQure (QURE) shares in 10b5-1 option exercise and sale - Stock Titan
Huntingtons Disease Market Size to Hit USD 6.48 Billion by 2035 - Precedence Research
Mizuho downgrades UniQure NV (QURE) - MSN
Form 144 uniQure N.V. For: 3 June By Investing.com - Investing.com South Africa
uniQure: Why A Shifting FDA Could Change Everything For AMT-130 (NASDAQ:QURE) - Seeking Alpha
Tracing UniQure's Tale Of Boom, Bust, And Rebound - RTTNews
(QURE) Volatility Zones as Tactical Triggers - Stock Traders Daily
uniQure stock surges 20% on Replimune FDA BLA news By Investing.com - Investing.com Australia
uniQure stock surges 20% on Replimune FDA BLA news - Investing.com
QURE News | UNIQURE NV (NASDAQ:QURE) - ChartMill
uniQure N.V. stock (IL0011559904): Gene therapy player navigates strategic reset and cash conservati - AD HOC NEWS
uniQure Q1 2026 Earnings: Narrower-Than-Expected Loss Amid No Revenue, Stock SlipsCapex Guidance - newsline.com
Numero AI and Royu Merge to Redefine How Finance Teams Operate - Benzinga
UniQure stock falls after FDA's notes on pre-application of AMT-130 - MSN
Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message - Insider Monkey
Uniqure NV at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
uniQure N.V. (QURE) Stalls at $24.84 — Breakout or Breakdown? 2026-05-19PCR Moving Average - newsline.com
Price-Driven Insight from (QURE) for Rule-Based Strategy - Stock Traders Daily
Huntington's Disease Pipeline 2026: Therapies Under - openPR.com
UniQure NV (QURE) price target decreased by 26.57% to 37.82 - MSN
Mizuho maintains uniQure NV (QURE) outperform recommendation - MSN
QURE stock just shot up 8%uniQure’s much-talked-about Huntington’s disease therapy gets a UK boost - MSN
UBS Group AG Buys 286,465 Shares of uniQure N.V. $QURE - MarketBeat
1.04%
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):